Capricor Therapeutics (CAPR) Net Margin (2011 - 2024)
Capricor Therapeutics (CAPR) recorded quarterly Net Margin of 243.08% in Q4 2024, up 143.78% quarter-over-quarter from 555.2% in Q3 2024, and up 24994.0% on a YoY basis from N/an in Q1 2024.
Capricor Therapeutics (CAPR) Net Margin (2011 - 2024) Analysis & Trends
Capricor Therapeutics' Net Margin history runs 14 years deep, the most recent figure standing at 243.08% for Q4 2024.
- In Q4 2024, Net Margin rose 24994.0% year-over-year to 243.08%; the TTM figure through Sep 2025 stood at 429.74% (down 30905.0% YoY), while the FY2024 annual figure was 181.71%, down 9294.0% from the prior year.
- Net Margin was 243.08% for Q4 2024 at Capricor Therapeutics, up from 555.2% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 243.08% in Q4 2024 to a low of 23187.59% in Q3 2020.
- Historically, Net Margin has averaged 3504.58% across 5 years, with a median of 477.75% in 2022.
- The sharpest annual moves came in 2020 and 2021: Net Margin plunged 2205675 bps in 2020, then jumped 450477 bps in 2021.
- A 5-year view of Net Margin shows it stood at 7224.51% in 2020, then soared by 66 bps to 2482.54% in 2021, then jumped by 68 bps to 800.77% in 2022, then surged by 99 bps to 6.86% in 2023, then surged by 3644 bps to 243.08% in 2024.
- The last three Net Margin figures came in at 243.08% (Q4 2024), 555.2% (Q3 2024), and 276.97% (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 0.82% |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Capricor Therapeutics | 1.53 Bn | 1.26 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 243.08% |
| Sep 30, 2024 | -555.20% |
| Jun 30, 2024 | -276.97% |
| Mar 31, 2024 | -97.94% |
| Dec 31, 2023 | -6.86% |
| Sep 30, 2023 | -103.22% |
| Jun 30, 2023 | -188.04% |
| Mar 31, 2023 | -260.10% |
| Dec 31, 2022 | -800.77% |
| Sep 30, 2022 | -400.30% |
| Jun 30, 2021 | -2,482.54% |
| Mar 31, 2021 | -12,622.31% |
| Dec 31, 2020 | -7,224.51% |
| Sep 30, 2020 | -23,187.59% |
| Jun 30, 2020 | -6,987.31% |
| Mar 31, 2020 | -1,122.72% |
| Dec 31, 2019 | -661.60% |
| Sep 30, 2019 | -1,130.84% |
| Jun 30, 2019 | -498.04% |
| Mar 31, 2019 | -1,092.97% |